Is lenalidomide a new standard treatment for myelodysplastic syndrome?

Affiliations

Comment

Andrea Kuendgen. Nat Clin Pract Oncol. 2007 Jul.

. 2007 Jul;4(7):396-7.

doi: 10.1038/ncponc0823. Epub 2007 May 15.

¹ Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany. andrea@ta2000.de

No abstract available

Comment on

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators. List A, et al. N Engl J Med. 2006 Oct 5;355(14):1456-65. doi: 10.1056/NEJMoa061292. N Engl J Med. 2006. PMID: 17021321 Clinical Trial.

Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Ortega J, List A. Ortega J, et al. Curr Opin Oncol. 2007 Nov;19(6):656-9. doi: 10.1097/CCO.0b013e3282f0e12b. Curr Opin Oncol. 2007. PMID: 17906467 Review.
The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C, Eclache V, Fenaux P. Kelaidi C, et al. Br J Haematol. 2008 Feb;140(3):267-78. doi: 10.1111/j.1365-2141.2007.06910.x. Br J Haematol. 2008. PMID: 18217896 Review.
Evaluation of the developmental toxicity of lenalidomide in rabbits.
Christian MS, Laskin OL, Sharper V, Hoberman A, Stirling DI, Latriano L. Christian MS, et al. Birth Defects Res B Dev Reprod Toxicol. 2007 Jun;80(3):188-207. doi: 10.1002/bdrb.20115. Birth Defects Res B Dev Reprod Toxicol. 2007. PMID: 17570132
A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.
Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. Mansfield JC, et al. Aliment Pharmacol Ther. 2007 Aug 1;26(3):421-30. doi: 10.1111/j.1365-2036.2007.03385.x. Aliment Pharmacol Ther. 2007. PMID: 17635377 Clinical Trial.
Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
Eclache V, Da Rocha A, Le Roux G, Fenaux P. Eclache V, et al. Haematologica. 2008 Feb;93(2):315-6. doi: 10.3324/haematol.11917. Haematologica. 2008. PMID: 18245660